1,025 results on '"Sitbon O"'
Search Results
2. Physiopathologie et traitement de l’hypertension artérielle pulmonaire
3. POS0221 CLUSTER ANALYSIS IDENTIFIES THREE CLINICAL PATTERNS OF PATIENTS WITH ANTI-KU ANTIBODIES: A MULTICENTRE STUDY OF 154 PATIENTS.
4. Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022
5. Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates With Hemodynamics and Is Consistent With REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
6. Therapeutic Implications of Plasma Proteome Clusters in Pulmonary Hypertension
7. Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH)
8. Disrupted BMP-9 signaling impairs pulmonary vascular integrity in hepatopulmonary syndrome
9. Medication adherence and related factors among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis
10. Transition et hypertension artérielle pulmonaire
11. Prise en charge de l’insuffisance ventriculaire droite aiguë compliquant les maladies vasculaires pulmonaires
12. Évolution de l’incidence de l’hypertension artérielle pulmonaire (HTAP) chez les patients suivis pour une infection par le VIH au cours des 15 dernières années
13. Hypertension pulmonaire associée à la gemcitabine : caractéristiques et évolution
14. Pulmonary hypertension due to left heart disease: First validation of the 2022 definitions in a prospective study, the PH-HF multicenter study
15. Suivi des patients atteints d’hypertension artérielle pulmonaire avec vasoréactivité en aigu et traités par inhibiteurs calciques : facteurs de risque d’échappement au traitement
16. Phénotypes cliniques et pronostiques associés aux anticorps anti-Ku déterminés par une analyse en clusters : une étude multicentrique de 154 patients
17. Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension
18. Hépatopathies et maladies vasculaires pulmonaires
19. La maladie veino-occlusive pulmonaire
20. Associations Between Serum Activin A and Follistatine-Like 3 Levels and Outcomes in Pulmonary Arterial Hypertension
21. ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension
22. Cytokines as Prognostic Biomarkers in Pulmonary Arterial Hypertension
23. A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication
24. (1) Severe Pediatric Pulmonary Arterial Hypertension. Long-Term Outcomes of Reverse Potts Shunt and Transplantation
25. Comprendre le cœur droit défaillant
26. Noninvasive prediction of pre-capillary pulmonary hypertension (PH) component in patients with post-capillary PH
27. Vasoréactivité aiguë dans l’hypertension pulmonaire sévère associée à la bronchopneumopathie chronique obstructive : quelle signification ?
28. Severe pediatric pulmonary arterial hypertension: Long-term outcomes of reverse Potts shunt and transplantation
29. Clinical phenotypes and outcomes of severe pulmonary hypertension associated with chronic obstructive pulmonary disease
30. Characteristics and management of chronic thromboembolic pulmonary disease patients without pulmonary hypertension in an expert centre
31. Risk stratification in pulmonary veno-occlusive disease
32. Cytokines as prognostic biomarkers in pulmonary arterial hypertension
33. Morphology and rheology of pulmonary arteries: A relationship with right ventricular function in patients with pulmonary arterial hypertension associated with atrial septal defect?
34. Prognostic value of hemodynamic parameters in pulmonary arterial hypertension associated to congenital heart diseases
35. Severe pediatric pulmonary arterial hypertension: Long-term outcomes of reverse Potts shunt and transplantation
36. Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension
37. Supplement to: Selexipag for the treatment of pulmonary arterial hypertension.
38. Prise en charge de l’hypertension artérielle pulmonaire
39. Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease
40. Deciphering a New Phenotype of Pulmonary Arterial Hypertension in Patients Carrying SOX17 Variants
41. External Validation of a Refined 4 Strata Risk Assessment Score from the French Pulmonary Hypertension Registry
42. Risk Stratification in Patients with Pulmonary Arterial Hypertension and Candidates for Lung or Heart-Lung Transplantation
43. Syndrome hépatopulmonaire : prévalence, physiopathologie et implications cliniques
44. (160) - Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH)
45. Facteurs pronostiques dans l’HTAP idiopathique
46. ERS statement on chronic thromboembolic pulmonary hypertension
47. Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method
48. Symptômes respiratoires et anomalies radiologiques dans le COVID long
49. Hypertension artérielle pulmonaire associée à la maladie de Still
50. Effet du traitement immunosuppresseur et du traitement spécifique dans l’HTAP associée au lupus érythémateux systémique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.